Related Experiment Videos
Alternating chemotherapy in small cell lung cancer
1Department of Internal Medicine, Philipps University Hospitals, Marburg, FRG.
Onkologie
|June 1, 1990
Summary
Rapid alternating chemotherapy shows mixed results for small cell lung cancer. While some studies suggest benefits, others find no difference compared to continuous therapy, indicating a need for further research.
Area of Science:
- Oncology
- Clinical Trials
- Cancer Therapeutics
Background:
- The Goldie and Coldman hypothesis suggests alternating chemotherapy may benefit small cell lung cancer.
- Numerous trials since the late 1970s have investigated this approach with varied outcomes.
Purpose of the Study:
- To evaluate the efficacy of rapid cyclic alternating chemotherapy versus continuous chemotherapy in small cell lung cancer.
- To clarify whether observed benefits are due to the alternating schedule or early introduction of novel agents.
Main Methods:
- Comparison of continuous standard therapy (CAV or CMC) with alternating schedules incorporating novel drugs like cisplatin and etoposide.
- Three-arm studies were designed to include continuous protocols as controls for alternating schedules.
Main Results:
- Two-arm trials showed improved results with alternating regimens, but causality was unclear.
- Three-arm studies yielded conflicting results, with one showing an advantage for alternating schedules and two showing no difference.
- Lack of standardized criteria for switching non-responding patients complicates interpretation.
Conclusions:
- The benefit of rapid cyclic alternating chemotherapy in small cell lung cancer remains inconclusive.
- Further research is needed to determine optimal chemotherapy strategies and address methodological limitations in trial design.